ArticleBMC infectious diseases2018
Identification of nine cryptic species of Candida albicans, C. glabrata, and C. parapsilosis complexes using one-step multiplex PCR.
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Nucleic Acid Amplification Tests forPathogens (Basel, Switzerland) · 2026Pooled it
- Can chlorhexidine gluconate baths reduce fungal colonisation in intensive care unit patients?Antimicrobial resistance and infection control · 2025Article
- Virulence Factors and Molecular Identification ofJournal of fungi (Basel, Switzerland) · 2025Article
- Reported prevalence and comparison of diagnostic approaches for Candida africana: a systematic review with meta-analysis.Diagnostic and prognostic research · 2024Review
- Susceptibility patterns ofInfection prevention in practice · 2024Article
- Insights intoJournal of fungi (Basel, Switzerland) · 2024Article
- Molecular Epidemiology and Antifungal Susceptibility Profile in Nakaseomyces glabrata Species Complex: A 5-Year Countrywide Study.Journal of clinical laboratory analysis · 2024Article
- Three cases of vulvovaginal candidiasis due toMedical mycology case reports · 2024Article
- The Emerging PathogenInfection and drug resistance · 2024Review
- Population genomic analyses reveal high diversity, recombination and nosocomial transmission amongMicrobial genomics · 2024Article
- Enhancing ICUFrontiers in cellular and infection microbiology · 2024Article
- Molecular Identification of Fungal Species through Multiplex-qPCR to Determine Candidal Vulvovaginitis and Antifungal Susceptibility.Journal of fungi (Basel, Switzerland) · 2023Article
- Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect againstMedicina (Kaunas, Lithuania) · 2023Article
- Evaluation ofCurrent medical mycology · 2022Article
- High frequency ofCurrent medical mycology · 2022Article
- Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs.Journal of fungi (Basel, Switzerland) · 2021Article
- Molecular Markers of Antifungal Resistance: Potential Uses in Routine Practice and Future Perspectives.Journal of fungi (Basel, Switzerland) · 2021Review
- Molecular Diagnosis of Yeast Infections.Current fungal infection reports · 2021Review
- A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women.Frontiers in microbiology · 2021Article
- Clonal Candidemia Outbreak byFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundCandida albicans, Candida glabrata, and Candida parapsilosis are three prevalent causes of candidiasis, worldwide. These species are considered as nine medically important complex species. Limited knowledge about these newly recognized species prompted us to develop a one-step, multiplex PCR to detect and identify them in clinical settings.
methodsPrimers targeting Hyphal Wall Protein I gene for the C. albicans, C. dubliniensis, C. africana, Intergenic Spacer for the C. glabrata, C. nivariensis, C. bracarensis, and Intein and ITS rDNA for the C. parapsilosis, C. orthopsilosis, and C. metapsilosis were designed. Using 168 CBS reference strains and 280 clinical isolates, the specificity and reproducibility of the developed assay were evaluated.
resultsOur developed assay successfully identified and distinguished all the nine species. No cross-reaction with closely- and distantly-related yeast species, Aspergillus species and human DNA was observed, resulting in 100% specificity. The ambiguous results obtained by MALDI-TOF for C. albicans and C. africana were corrected by our 9-plex PCR assay. This assay identified all the cryptic complex species from two test sets from Iran and China, correctly.
conclusionsOur developed multiplex assay is accurate, specific, cost/time-saving, and works without the tedious DNA extraction steps. It could be integrated into routine clinical laboratories and as a reliable identification tool and has the potential to be implemented into epidemiological studies to broaden the limited knowledge of cryptic species complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.